$BCRX

$8.09 +$0.21 (2.66%) Live

$BCRX Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Ownership

13F as of Q2 2026 · 255.5M shares outstanding

Who owns BCRX?

By type of holder

Institutions 100.0% Insiders 0.0% Everyone else 0.0%

Concentration Top 10 holders own 51.5%

BlackRock, Inc. 9.4% · Ra Capital Management, L.P. 6.2%

Institutional ownership

100.0%

+2.5 pts vs last qtr

Institutional holders

316

+14 vs last qtr

Net shares bought

+10.7M

by institutions in Q2 2026

New / sold out

55 / 41

positions opened vs closed

How is ownership changing?

Institutions, last 8 quarters

Biggest buyers in Q2 2026

Jupiter Topco LLC NEW +9.5M
Millennium Management LLC +3.2M

Biggest sellers in Q2 2026

Janus Henderson Group PLC SOLD OUT −8.9M
Royalty Pharma Sub-Manager, LLC SOLD OUT −3.8M

Who is planning to sell?

Notices of proposed sale, last 12 months

$7.42M

13 notices from 7 people

Shares covered

885.4K

0.35% of the company

Arranged in advance

78%

of the value is under a 10b5-1 plan

Under a 10b5-1 plan No plan

Largest proposed sellers

Barnes Alane P Officer $3.46M
Stonehouse Jon P Director 10b5-1 $2.65M

Every notice on Red Flags →

A Form 144 is notice of a planned sale, not the sale itself. What insiders actually sold is on Insider Transactions.

Is your stake being diluted?

Diluted share count, FY2016–FY2025

+196.6%

+12.84% a year

Each share's claim on the business

−66.3%

shrank without buying or selling a share

Spent on buybacks vs paid in stock

— vs $348M

over 10 fiscal years

Diluted shares, split-adjusted

Buybacks Stock-based comp

How patient are the owners?

Institutional shares by how long they've been held

5+ years48% 3–5 years10% 1–3 years7% Under 1 year35%

Quarterly turnover

16.2%

of institutional shares changed hands

Top 10 managers, median time held

3.3 years

Super Investors

Investment managers reporting BCRX on Form 13F

Holder	Shares	% of company	Change vs last qtr	Held since	% of their book
B BlackRock, Inc.	23.9M	9.35%	+1.2M (+5.5%)	≤2021	0.0%
Shares held by quarter Peak holding23.9M (Q2'26) Change over 8 quarters+3.0M Share of the company9.350% BlackRock, Inc.'s full portfolio →
RC Ra Capital Management, L.P.	15.8M	6.19%	Unchanged	Q4 '25	1.4%
Shares held by quarter Peak holding15.8M (Q4'25) Change over 8 quarters+15.8M Share of the company6.190% Ra Capital Management, L.P.'s full portfolio →

BlackRock, Inc.

23.9M

% of company

9.35%

Change vs last qtr

+1.2M (+5.5%)

Held since

≤2021

Ra Capital Management, L.P.

15.8M

% of company

6.19%

Change vs last qtr

Unchanged

Held since

Q4 '25

28 more super investors behind a free account

See every manager holding BioCryst Pharmaceuticals, Inc., how their position has changed, and how long they've held it.

Institutional Funds

Mutual funds and ETFs reporting BCRX on Form N-PORT; together they hold 30.4% of the company

Fund	Position value	Shares	% of company	% of the fund	As of
SS State Street(R) SPDR(R) S&P(R) Biotech ETF SPDR Series Trust	$95.8M	9.6M	3.75%	0.89%	June 30, 2026
VT Vanguard Total Stock Market Index Fund Vanguard Index Funds	$80.7M	8.1M	3.16%	0.00%	June 30, 2026

State Street(R) SPDR(R) S&P(R) Biotech ETF

SPDR Series Trust

Position value

$95.8M

% of company

3.75%

% of the fund

0.89%

As of

June 30, 2026

Vanguard Total Stock Market Index Fund

Vanguard Index Funds

Position value

$80.7M

% of company

3.16%

% of the fund

0.00%

As of

June 30, 2026

23 more funds behind a free account

See every fund holding BioCryst Pharmaceuticals, Inc. and how much of the fund the position is.

Insiders and 5%+ holders

From Forms 3/4/5 and Schedules 13D/G

Holder	Shares	% of company	Change vs last qtr	8 quarters	Held since	% of their book
SJ Stonehouse Jon P Insider	1.4M	0.56%	—	—	—	—
Insider holdings come from Form 3/4/5 filings, which are not quarterly. Share of the company0.560% Stonehouse Jon P's insider activity →
GC Gayer Charles K Insider	952.6K	0.37%	—	—	—	—
Insider holdings come from Form 3/4/5 filings, which are not quarterly. Share of the company0.370% Gayer Charles K's insider activity →

Stonehouse Jon P

Insider

1.4M

% of company

0.56%

Change vs last qtr

—

Held since

—

Gayer Charles K

Insider

952.6K

% of company

0.37%

Change vs last qtr

—

Held since

—

15 more holders behind a free account

See every insider and 5%+ holder of BioCryst Pharmaceuticals, Inc..

Comments